US-based pharmaceutical giant Pfizer Inc. shares surged more than 7% during the intraday session on Wall Street after United States President Donald Trump announced that the company plans to reduce in the United States.
Trump on Tuesday said that Pfizer will cut the price of all prescription drugs in the Medicaid program for low-income US citizens and sell new prescription drugs at a “most favoured nation” price in exchange for tariff relief.
also announced that he expects other drugmakers to also follow Pfizer’s lead and cut prices for drugs sold to American citizens.
“The United States is done subsidising the healthcare of the rest of the world,” said Trump, speaking to the media along with Pfizer CEO Albert Bourla and other executives.
Trump earlier announced a 100% conditional into the United States, effective Wednesday, 1 October 2025.
Pfizer Share Price Trend
Pfizer Inc. share price closed 6.69% higher at $25.45 after Tuesday’s Wall Street session, compared to $23.85 at the previous market close. The company’s stock jumped more than 7% during Tuesday’s intraday session to its high level of $25.63.
Shares of the pharma company lost 26% in the last five years and are trading 11.96% lower in the last one-year period. On a year-to-date (YTD) basis, Pfizer shares are down 4.25% in 2025.
However, Pfizer stock has given more than 2% returns on their investment in the last one-month period, and the shares are trading over 5% in the last five market sessions on Wall Street.
According to the data collected from MarketWatch, the company shares hit their 52-week high level at $30.43, while the 52-week low level stood at $20.92. The company’s market capitalisation (M-Cap) stood at $135.6 billion as of the stock market session on Tuesday, 30 September 2025.
As per the after-hours market session on Wall Street, the shares of the pharma major were trading 0.27% lower at $25.41, compared to the market close at $25.48.
Read all stories by
Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.